Trial Profile
An Open-label study to evaluate the steady state pharmacokinetics of FDC of darunavir/cobicistat and atazanavir/cobicistat following drug intake cessation
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 20 Apr 2017
Price :
$35
*
At a glance
- Drugs Atazanavir/cobicistat (Primary) ; Cobicistat/darunavir (Primary)
- Indications HIV-1 infections
- Focus Pharmacokinetics
- 20 Apr 2017 New trial record
- 12 Apr 2017 Results published in the Journal of Antimicrobial Chemotherapy